Company History

History Image

Cerimon Pharmaceuticals, Inc. was founded in November 2004 by Paul Sekhri with Ansbert Gadicke and Luke Evnin from MPM Capital. In October 2005, Cerimon completed a $70M financing with MPM Capital, Nomura Phase4 Ventures, OrbiMed Advisors and Stanford University. In its first year of business, Cerimon secured rights to two products, Simulect® and a diclofenac patch, for testing in new indications.

Corporate Timeline
  • November 2009 Cerimon acquires European rights to Topical Diclofenac Patch
  • February 2009 Cerimon initiates its diclofenac patch Phase III clinical trials
  • January 2009 James Shannon appointed President and Chief Executive Officer of Cerimon
  • September 2008 Cerimon obtains positive results from a Phase II study of its topical diclofenac patch
  • July 2008 Cerimon initiates a proof of concept study with Simulect® in noninfectious uveitis
  • December 2007 Cerimon initiates Phase II studies of its topical diclofenac patch
  • September 2007 Cerimon acquires U.S. rights to market and sell an additional topical lotion formulation for diclofenac sodium
  • September 2007 Cerimon initiates a Phase I study of its topical diclofenac patch
  • March 2007 Cerimon initiates a Phase IIb study of Simulect® for the treatment of ulcerative colitis in moderate-to-severe, steroid-refractory patients
  • February 2006 Cerimon acquires exclusive worldwide rights to Simulect® (basiliximab) for the treatment of Inflammatory Bowel Disease
  • October 2005 Cerimon completes a $70M financing with MPM Capital, Nomura Phase4 Ventures, OrbiMed Advisors and Stanford University
  • July 2005 Cerimon secures U.S. rights to market and sell a topical patch formulation of diclofenac sodium
  • November 2004 Cerimon Pharmaceuticals, Inc. is founded by Paul Sekhri with Ansbert Gadicke and Luke Evnin from MPM Capital